Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.69 USD | -1.33% | +5.02% | +26.94% |
May. 07 | Bioventus Inc. Revises Earnings Guidance for the Full-Year 2024 | CI |
May. 07 | Transcript : Bioventus Inc., Q1 2024 Earnings Call, May 07, 2024 |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- Low profitability weakens the company.
- The group shows a rather high level of debt in proportion to its EBITDA.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+26.94% | 427M | C | ||
+75.69% | 12.57B | B- | ||
-24.68% | 7.34B | C+ | ||
+12.58% | 5.39B | D+ | ||
-16.63% | 4.84B | B | ||
+26.90% | 4.53B | - | ||
-21.14% | 3.91B | B- | ||
-22.99% | 2.91B | C | ||
+47.42% | 2.37B | C- | ||
-0.37% | 2B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- BVS Stock
- Ratings Bioventus Inc.